

Open session of the Standing Technical and Research Committees of the EuFMD

Cavtat (Croatia), 29-31 october 2014





WHOLE GENOME SEQUENCING OF FMDV: DEVELOPMENT OF PROTOCOLS AND APPLICATION TO A LARGE OUTBREAK

Graham Freimanis

Non-Vesicular Reference Lab, The Pirbright Institute










Next Generation Sequencing (NGS)




Why Use NGS?


Previous strategies (i.e. Sanger sequencing) subject to:

- limited throughput/labour intensive
- Subject to a priori knowledge for sequencing i.e. primers, variation


Criteria for inclusion in protocol development:

- Reduce Bias: 'No-PCR'
- **2. Whole genome coverage**: S and L fragments (polyC tract)
- 3. Applicable to other viruses
- 4. Consensus-level or deeper
- 5. Potential for high-throughput







Protocol sensitivity: viral loads >10⁶ copies/μl



Depletion of host genomic DNA increases the proportion of viral reads




FMDV Serotype Coverage



▲ Genome coverage of 5 UK 2001 field isolates






▲ Genome coverage of 7 FMDV serotypes




Other Applications



Genome Position

WGS of viruses unable to grow in culture (FMDV O/ISR/2/2013) ▶

Family	Genus	Species
Picornaviridae	Aphthovirus	Foot-and-mouth
		disease virus
		(FMDV)
		Equine rhinitis A
		virus (EMCV)
		[Beige]
	Cardiovirus	Encephalomyocard
		itis virus (ERAV)
		[Black]
Caliciviridae	Vesivirus	Vesicular
		exanthema of
		swine virus (VESV)
		[Blue]



Summary I


- 'No-PCR' protocol for WGS of FMDV
- Limit of Detection: >10⁶ copies/μl
- Able to sequence all 7 serotypes of FMDV
- Able to sequence other viruses (non-FMDV)
- Able to sequence viruses without amplification (culture)

Application: UK 2001 Outbreak

- 2026 IP's confirmed/1300 samples
- **Economic impact**: > £2billion
- Aim: Apply WGS to give a fine point resolution to outbreak tracing


Adapt protocol to high-throughput format (i.e. 96 samples) @consensus level


- 88 samples, 8 controls
- 24 samples repeated 24 format
- **FMDV**: SAT1/2/3/UKG/Prev Pos
- Non-FMDV : ERAV/EMCV/VESV



Picture source: Telegraph: http://www.telegraph.co.uk/earth/agriculture/8335705/Farmers-rise-from-the-ashes-of-foot-and-mouth.html


Recovery of 5' genomic termini





5' genomic termini recovery - 24 and 96 sample format

Cross-reactivity between samples



▲ Cross reactivity between FMDV samples against EMCV and VESV reference genome

Validation with Sanger Sequencing

4 Samples previously sequenced using Sanger sequencing (gold standard):

- 3/4 consensus identical with Sanger sequences
- 1/4 differed by one position (ambiguous in Sanger)


8 controls on run validated

24 and 96 sample formats:

Both gave identical consensus

Applications I: Outbreak 96 Sample run **Tracing** ▲ Repeats of previously published (Sanger) **Previously published** sequences (NCBI)

Application II: Consensus Similarity



Summary II

- Protocol successfully generates consensus level (or deeper) sequence for whole FMDV genomes (BMC Genomics, 2014)
- 5' genomic termini dependent upon viral load
- No detectable cross-reactivity
- Adaptable for high-throughput format (96 samples) application for larger outbreaks
- Sequencing of UK 2001 outbreak ongoing

Acknowledgements

The Pirbright Institute:

- Grace Logan
- David King
- Kasia Bankowska
- Begona Valdazo-Gonzalez
- Nick Sanderson
- Nick Knowles
- Donald King
- Eleanor Cottam
- Valerie Mioulet & WRLFMD

University of Glasgow:

Richard Orton

The Epi-Seq Consortium







